WO2008090742A1 - 眼疾患モデル用非ヒト動物 - Google Patents

眼疾患モデル用非ヒト動物 Download PDF

Info

Publication number
WO2008090742A1
WO2008090742A1 PCT/JP2008/000069 JP2008000069W WO2008090742A1 WO 2008090742 A1 WO2008090742 A1 WO 2008090742A1 JP 2008000069 W JP2008000069 W JP 2008000069W WO 2008090742 A1 WO2008090742 A1 WO 2008090742A1
Authority
WO
WIPO (PCT)
Prior art keywords
eye disease
model
human animal
animal
naturally occurring
Prior art date
Application number
PCT/JP2008/000069
Other languages
English (en)
French (fr)
Inventor
Keiko Fujikawa
Kaoru Inoue
Original Assignee
National University Corporation Hokkaido University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by National University Corporation Hokkaido University filed Critical National University Corporation Hokkaido University
Priority to JP2008555002A priority Critical patent/JP5087011B2/ja
Priority to US12/524,268 priority patent/US8304601B2/en
Publication of WO2008090742A1 publication Critical patent/WO2008090742A1/ja

Links

Classifications

    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; CARE OF BIRDS, FISHES, INSECTS; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K67/00—Rearing or breeding animals, not otherwise provided for; New breeds of animals
    • A01K67/027—New breeds of vertebrates
    • A01K67/0275—Genetically modified vertebrates, e.g. transgenic
    • A01K67/0276—Knockout animals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4702—Regulators; Modulating activity
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; CARE OF BIRDS, FISHES, INSECTS; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2217/00—Genetically modified animals
    • A01K2217/07—Animals genetically altered by homologous recombination
    • A01K2217/075—Animals genetically altered by homologous recombination inducing loss of function, i.e. knock out
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; CARE OF BIRDS, FISHES, INSECTS; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2227/00—Animals characterised by species
    • A01K2227/10—Mammal
    • A01K2227/105—Murine
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; CARE OF BIRDS, FISHES, INSECTS; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2267/00—Animals characterised by purpose
    • A01K2267/03—Animal model, e.g. for test or diseases
    • A01K2267/035—Animal model for multifactorial diseases
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/16—Ophthalmology

Abstract

 自然発生的に眼疾患症状、特に高眼圧及び／又は網膜変性を呈するモデル動物の提供を目的とする。  本発明はＶａｖ２遺伝子及び／又はＶａｖ３遺伝子の機能を欠損させた眼疾患モデル用非ヒト動物に関する。当該動物は、薬物の投与や特殊な生育環境に置くことなく、自然発症的に高眼圧及び／又は網膜変性等の眼疾患症状を呈することから、眼疾患発症機構の解明や眼疾患治療薬評価の有用なモデルとして利用できる。これらの利用の場合、従来人為的に眼疾患を誘発するために投与される外来性因子の影響を受けることがないため自然病態を反映しており、臨床的また産業的な有用性が高い。
PCT/JP2008/000069 2007-01-23 2008-01-23 眼疾患モデル用非ヒト動物 WO2008090742A1 (ja)

Priority Applications (2)

Application Number Priority Date Filing Date Title
JP2008555002A JP5087011B2 (ja) 2007-01-23 2008-01-23 眼疾患モデル用非ヒト動物
US12/524,268 US8304601B2 (en) 2007-01-23 2008-01-23 Mouse model for eye disease

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2007-012458 2007-01-23
JP2007012458 2007-01-23

Publications (1)

Publication Number Publication Date
WO2008090742A1 true WO2008090742A1 (ja) 2008-07-31

Family

ID=39644317

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/JP2008/000069 WO2008090742A1 (ja) 2007-01-23 2008-01-23 眼疾患モデル用非ヒト動物

Country Status (3)

Country Link
US (1) US8304601B2 (ja)
JP (1) JP5087011B2 (ja)
WO (1) WO2008090742A1 (ja)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR102177174B1 (ko) 2018-05-18 2020-11-10 울산대학교 산학협력단 Pde6b 유전자가 결손된 망막 변성 동물 모델 및 이의 제조 방법
KR102234258B1 (ko) * 2019-01-28 2021-03-31 경북대학교 산학협력단 안압이 상승된 동물 모델, 그의 제조방법 및 그를 이용한 녹내장 치료제의 스크리닝 방법

Family Cites Families (47)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IT1251144B (it) * 1991-07-30 1995-05-04 Boehringer Ingelheim Italia Derivati del benzimidazolone
US5407686A (en) * 1991-11-27 1995-04-18 Sidmak Laboratories, Inc. Sustained release composition for oral administration of active ingredient
US5492907A (en) * 1992-12-09 1996-02-20 The United States Of America As Represented By The Department Of Health & Human Services Antipsychotic composition and method of treatment
US5552412A (en) * 1995-01-09 1996-09-03 Pfizer Inc 5-substitued-6-cyclic-5,6,7,8-tetrahydronaphthalen2-ol compounds which are useful for treating osteoporosis
US5916916A (en) * 1996-10-10 1999-06-29 Eli Lilly And Company 1-aryloxy-2-arylnaphthyl compounds, intermediates, compositions, and methods
JP2001504851A (ja) * 1996-12-02 2001-04-10 メルク シヤープ エンド ドーム リミテツド 性的機能不全の治療のためのｎｋ−１受容体拮抗薬の使用
DE69815003T2 (de) * 1997-09-10 2004-04-01 Takeda Chemical Industries, Ltd. Stabilisierte pharmazeutische Zusammensetzung
CH692199A8 (fr) * 1997-10-09 2002-06-14 Cermol S.A. Composes pyridiques et compositions pharmaceutique
JP3724157B2 (ja) * 1997-10-30 2005-12-07 コニカミノルタホールディングス株式会社 映像観察装置
US20020151543A1 (en) * 1998-05-28 2002-10-17 Sepracor Inc. Compositions and methods employing R (-) fluoxetine and other active ingredients
US6068846A (en) * 1998-08-05 2000-05-30 Melaleuca, Incorporated Methods and materials for treating depression and mood disorder
US6346548B1 (en) * 1999-08-16 2002-02-12 Cephalon, Inc. Compositions including modafinil for treatment of attention deficit hyperactivity disorder and multiple sclerosis fatigue
IT1313625B1 (it) * 1999-09-22 2002-09-09 Boehringer Ingelheim Italia Derivati benzimidazolonici aventi affinita' mista per i recettori diserotonina e dopamina.
NZ520975A (en) * 2000-02-24 2004-03-26 Upjohn Co New drug combinations containing a norepinephrine reuptake inhibitor and an antimuscarinic agent for treating nervous system disorders
US6586435B2 (en) * 2000-09-19 2003-07-01 Boehringer Ingelheim Pharma Kg Benzimidazolone derivatives displaying affinity at the serotonin and dopamine receptors
US6521623B1 (en) * 2000-09-19 2003-02-18 Boehringer Ingelheim Pharma Kg N,N'-disubstituted benzimidazolone derivatives with affinity at the serotonin and dopamine receptors
US6627646B2 (en) * 2001-07-17 2003-09-30 Sepracor Inc. Norastemizole polymorphs
US7183410B2 (en) * 2001-08-02 2007-02-27 Bidachem S.P.A. Stable polymorph of flibanserin
US20030060475A1 (en) * 2001-08-10 2003-03-27 Boehringer Ingelheim Pharma Kg Method of using flibanserin for neuroprotection
UA78974C2 (en) * 2001-10-20 2007-05-10 Boehringer Ingelheim Pharma Use of flibanserin for treating disorders of sexual desire
US20040048877A1 (en) * 2002-05-22 2004-03-11 Boehringer Ingelheim Pharma Gmbh & Co. Kg Pharmaceutical compositions containing flibanserin
US20040132697A1 (en) * 2002-11-06 2004-07-08 Pfizer Inc. Treatment of female sexual dysfunction
US20050239798A1 (en) * 2004-04-22 2005-10-27 Boehringer Ingelheim Pharmaceuticals, Inc. Method for the treatment of premenstrual and other female sexual disorders
KR20070014184A (ko) * 2004-04-22 2007-01-31 베링거 인겔하임 인터내셔날 게엠베하 성기능 장애 치료용 신규 약제학적 조성물 ⅱ
US20060014757A1 (en) * 2004-07-14 2006-01-19 Boehringer Ingelheim Pharmaceuticals Method for the treatment of anorexia nervosa
US20060025420A1 (en) * 2004-07-30 2006-02-02 Boehringer Ingelheimn International GmbH Pharmaceutical compositions for the treatment of female sexual disorders
WO2006024471A1 (en) * 2004-09-03 2006-03-09 Boehringer Ingelheim International Gmbh Method for the treatment of attention deficit hyperactivity disorder
US20060199805A1 (en) * 2005-03-04 2006-09-07 Boehringer Ingelheim International Gmbh Pharmaceutical compositions for the treatment and/or prevention of anxiety disorders
WO2006096439A2 (en) * 2005-03-04 2006-09-14 Boehringer Ingelheim International Gmbh Pharmaceutical compositions for the treatment and/or prevention of schizophrenia and related diseases
CA2599721A1 (en) * 2005-03-04 2006-09-14 Boehringer Ingelheim International Gmbh Pharmaceutical compositions for the treatment and/or prevention of depression
JP2008540356A (ja) * 2005-05-06 2008-11-20 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング 薬物乱用の治療方法
US20060258640A1 (en) * 2005-05-13 2006-11-16 Boehringer Ingelheim International Gmbh Use of Flibanserin in the treatment of chronic pain
WO2006125042A1 (en) * 2005-05-19 2006-11-23 Boehringer Ingelheim International Gmbh Method for the treatment of drug-induced sexual dysfunction
JP2008540672A (ja) * 2005-05-19 2008-11-20 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング 病状に起因する性的機能不全の治療方法
WO2007014929A1 (en) * 2005-08-03 2007-02-08 Boehringer Ingelheim International Gmbh Use of flibanserin in the treatment of obesity
WO2007048803A1 (en) * 2005-10-29 2007-05-03 Boehringer Ingelheim International Gmbh Benzimidazolone derivatives for the treatment of premenstrual and other female sexual disorders
US20070123540A1 (en) * 2005-10-29 2007-05-31 Angelo Ceci Sexual desire enhancing medicaments comprising benzimidazolone derivatives
US20070105869A1 (en) * 2005-11-08 2007-05-10 Stephane Pollentier Use of flibanserin for the treatment of pre-menopausal sexual desire disorders
CA2641917A1 (en) * 2006-02-18 2007-08-23 Boehringer Ingelheim International Gmbh Pharmaceutical compositions for the treatment of attention deficit hyperactivity disorder comprising flibanserin
EP1988897A1 (en) * 2006-02-20 2008-11-12 Boehringer Ingelheim International GmbH Benzimidazolone derivatives for the treatment of urinary incontinence
EP1991228A1 (en) * 2006-02-28 2008-11-19 Boehringer Ingelheim International GmbH Treatment of prevention of valvular heart disease with flibanserin
KR20090005371A (ko) * 2006-05-09 2009-01-13 베링거 인겔하임 인터내셔날 게엠베하 폐경후 성욕 장애의 치료를 위한 플리반세린의 용도
WO2008000760A1 (en) * 2006-06-30 2008-01-03 Boehringer Ingelheim International Gmbh Flibanserin for the treatment of urinary incontinence and related diseases
US20090239881A1 (en) * 2006-07-14 2009-09-24 Boehringer Ingelheim International Gmbh Combinations of Flibanserin with Caffeine, Process for Their Preparation and Use Thereof as Medicaments
JP2009543839A (ja) * 2006-07-14 2009-12-10 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング 女性の性的障害を治療するためのフリバンセリンの使用
EP2054041A2 (en) * 2006-08-14 2009-05-06 Boehringer Ingelheim International GmbH Formulations of flibanserin and method for manufacturing the same
CN101505736A (zh) * 2006-08-25 2009-08-12 贝林格尔.英格海姆国际有限公司 控制释放系统及其制造方法

Non-Patent Citations (5)

* Cited by examiner, † Cited by third party
Title
AIHARA H.: "Dobutsu Model o Tsukatta Jikken", PRACTICAL OPHTHALMOLOGY, 3 September 2006 (2006-09-03), pages 378 - 379 *
AIHARA H.: "Idenshi Kaihen Dobutsu o Mochiita Yakubutsu Kaihatsu -Ryokunaisho, Shinkei Shikkan Chiryo eno Oyo-", JAPANESE JOURNAL OF OCULAR PHARMACOLOGY, vol. 20, no. 1, 8 September 2006 (2006-09-08), pages 59 - 62 *
FUJIKAWA K. ET AL.: "Vav /2/3-null Mice Define an Essential Role for Vav Family Proteins in Lymphocyte Development and Activation but a Differential Requirement in MAPK Signaling in T and B Cells", THE JOURNAL OF EXPERIMENTAL MEDICINE, vol. 198, no. 10, 17 November 2003 (2003-11-17), pages 1595 - 1608 *
FUJIKAWA K. ET AL.: "Vav Family Bunshi no NK Saibo deno Hataraki - NKG2D/DAP, DAP12 o Kaisuru Saibo Shogai Sayo Signaling Keiro eno Kotonatta Kan'yo", DAI 34 KAI THE JAPANESE SOCIETY FOR IMMUNOLOGY.GAKUJUTSU SHUKAI, 5 November 2004 (2004-11-05), pages 333 *
GINA M.D. ET AL.: "Signal transduction through Vav-2 participates in humoral immune responses and B cell maturation", NATURE IMMUNOLOGY, vol. 2, no. 6, 2001, pages 537 - 541 *

Also Published As

Publication number Publication date
US20100031379A1 (en) 2010-02-04
JPWO2008090742A1 (ja) 2010-05-20
JP5087011B2 (ja) 2012-11-28
US8304601B2 (en) 2012-11-06

Similar Documents

Publication Publication Date Title
Office of the Surgeon General (US The Surgeon General's vision for a healthy and fit nation
EP2510811A3 (en) Use of nutritional compositions for preventing disorders
MX2009005644A (es) Gel util para el suministro de farmacos oftalmicos.
MX2009005279A (es) Derivados de n-(metil)-1h-pirazol-3-amina, n-(metil)-piridin-2-ami na y n-(metil)-tiazol-2-amina para el tratamiento de enfermedades asociadas con proteinas amiloides o tipo amiloide, tal como por ejemplo alzheimer.
WO2005079774A3 (en) Management of ophthalmologic disorders, including macular degeneration
Yamada et al. Implanted cannula-mediated repetitive administration of Aβ25–35 into the mouse cerebral ventricle effectively impairs spatial working memory
EP2322219A3 (en) Use of IL-23 and IL-17 antagonists to treat autoimmune ocular inflammatory disease
EP2407171A3 (en) Compositions and methods for the treatment of ophthalmic disease
WO2007035473A3 (en) Pharmaceutical delivery device and method for providing ocular treatment
IL195626A (en) Use of an ophthalmic device containing at least one prescription drug in combination with any carrier suitable for the provision of an eye for the preparation of a drug or an ophthalmic drug for the treatment of the disease in the back of the eye in a person or animal
EP2386299A3 (en) 1-Amino-Alkylcyclohexane derivatives for the treatment of cochlear tinnitus
EP2468282A3 (en) Methods and products for treatment of diseases
EP1808170A4 (en) AQUEOUS EYE DROPS WITH ACCELERATED INTRAOCULAR MIGRATION
WO2004101752A3 (en) Compounds for treatment of inflammation, diabetes and related disorders
US10258611B2 (en) Combination of ibudilast and riluzole and methods of using same
WO2008090742A1 (ja) 眼疾患モデル用非ヒト動物
WO2005117577A3 (en) Model for neurodegenerative disorders
DK2488513T3 (da) 2,6-Diaminopyridinforbindelser til behandling af sygdomme forbundet med amyloidproteiner eller til behandling af øjensygdomme
WO2008122032A3 (en) Treatment method for mmp-implicated pathologies
NO20054389L (no) Cyckloalkyl-substituerte alkansyrederivater, fremgangsmate for fremstilling og anvendelse derav som legemiddel
WO2008070311A3 (en) Gene expression profiling of parkinson's disease
EA200970562A1 (ru) Применение l-карнитина для получения лекарственного средства в форме глазных капель для лечения заболеваний роговицы
NO20055889L (no) 2-etoksy-3-fenylpropansyrederivater for behandling av fettforstyrrelser
EP1854477A3 (en) Compositions and methods for treating ophthalmic disorders
BR112012010179A2 (pt) métodos para manter a saúde do olho e melhorar as doenças oftálmicas em caninos.

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 08702810

Country of ref document: EP

Kind code of ref document: A1

ENP Entry into the national phase

Ref document number: 2008555002

Country of ref document: JP

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: 12524268

Country of ref document: US

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 08702810

Country of ref document: EP

Kind code of ref document: A1